Shalini S Mohan1,2, Matthew W Knuiman3, Mark L Divitini3, Alan L James1,4, Arthur W Musk1,3,5, David J Handelsman6, Jonathan Beilin7, Michael Hunter3,8, Bu B Yeap1,2. 1. School of Medicine and Pharmacology, University of Western Australia, Perth, WA, Australia. 2. Department of Endocrinology and Diabetes, Fremantle and Fiona Stanley Hospitals, Perth, WA, Australia. 3. School of Population Health, University of Western Australia, Perth, WA, Australia. 4. Department of Pulmonary Physiology and Sleep Medicine, Sir Charles Gairdner Hospital, Nedlands, WA, Australia. 5. Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands, WA, Australia. 6. ANZAC Research Institute and University of Sydney, Sydney, NSW, Australia. 7. Department of Endocrinology and Diabetes, Royal Perth Hospital, Perth, WA, Australia. 8. Busselton Population Medical Research Institute, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.
Abstract
OBJECTIVES: Lower circulating androgens and poorer lung function are associated with increased cardiovascular risk and mortality in men. The association between androgens and lung function is unclear. We tested the hypothesis that circulating testosterone (T) and its metabolites dihydrotestosterone (DHT) and oestradiol (E2) are differentially associated with lung function in men. METHODS: Early-morning serum T, DHT and E2 were assayed using mass spectrometry in 1768 community-dwelling men from Busselton, Western Australia. Forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC) were measured using spirometry. Linear regression models adjusting for age, height, smoking, exercise, body mass index, respiratory conditions and cardiovascular risk factors were used. RESULTS: Mean age was 50.1 ± 16·8 years. 16·0% were current smokers, 14·1% reported a history of asthma and 2·7% reported chronic obstructive pulmonary disease. Current smokers had higher T compared with never smokers (age-adjusted mean 14·5 vs 13·5 nmol/l, P = 0·002) and higher E2 (65·3 vs 60·1 pmol/l, P = 0·017). In fully adjusted analyses, T was associated with FEV1 (51 ml per 1 SD increase, P < 0·001) as was DHT (62 ml, P < 0·001), E2 was not (P = 0·926). Similar results were seen for FVC (T: 76 ml, P < 0·001; DHT: 65 ml, P < 0·001; E2 P = 0·664). Higher DHT was marginally associated with the ratio FEV1/FVC (0·3% per 1 SD increase, P = 0·047). CONCLUSIONS: Both T and DHT were independently associated with higher FEV1 and FVC in predominantly middle-aged community-dwelling men. Androgens may contribute to, or be biomarkers for, better lung function in men. Further research is needed to clarify whether androgens preserve lung function in ageing men.
OBJECTIVES: Lower circulating androgens and poorer lung function are associated with increased cardiovascular risk and mortality in men. The association between androgens and lung function is unclear. We tested the hypothesis that circulating testosterone (T) and its metabolites dihydrotestosterone (DHT) and oestradiol (E2) are differentially associated with lung function in men. METHODS: Early-morning serum T, DHT and E2 were assayed using mass spectrometry in 1768 community-dwelling men from Busselton, Western Australia. Forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC) were measured using spirometry. Linear regression models adjusting for age, height, smoking, exercise, body mass index, respiratory conditions and cardiovascular risk factors were used. RESULTS: Mean age was 50.1 ± 16·8 years. 16·0% were current smokers, 14·1% reported a history of asthma and 2·7% reported chronic obstructive pulmonary disease. Current smokers had higher T compared with never smokers (age-adjusted mean 14·5 vs 13·5 nmol/l, P = 0·002) and higher E2 (65·3 vs 60·1 pmol/l, P = 0·017). In fully adjusted analyses, T was associated with FEV1 (51 ml per 1 SD increase, P < 0·001) as was DHT (62 ml, P < 0·001), E2 was not (P = 0·926). Similar results were seen for FVC (T: 76 ml, P < 0·001; DHT: 65 ml, P < 0·001; E2 P = 0·664). Higher DHT was marginally associated with the ratio FEV1/FVC (0·3% per 1 SD increase, P = 0·047). CONCLUSIONS: Both T and DHT were independently associated with higher FEV1 and FVC in predominantly middle-aged community-dwelling men. Androgens may contribute to, or be biomarkers for, better lung function in men. Further research is needed to clarify whether androgens preserve lung function in ageing men.
Authors: Natalia Weare-Regales; Sergio E Chiarella; Juan Carlos Cardet; Y S Prakash; Richard F Lockey Journal: J Allergy Clin Immunol Pract Date: 2022-04-15
Authors: MeiLan K Han; Emilio Arteaga-Solis; John Blenis; Ghada Bourjeily; Deborah J Clegg; Dawn DeMeo; Jeanne Duffy; Ben Gaston; Nicola M Heller; Anna Hemnes; Elizabeth Petri Henske; Raksha Jain; Tim Lahm; Lisa H Lancaster; Joyce Lee; Marianne J Legato; Sherry McKee; Reena Mehra; Alison Morris; Y S Prakash; Martin R Stampfli; Rashmi Gopal-Srivastava; Aaron D Laposky; Antonello Punturieri; Lora Reineck; Xenia Tigno; Janine Clayton Journal: Am J Respir Crit Care Med Date: 2018-10-01 Impact factor: 21.405
Authors: Sandeep Dhindsa; Nan Zhang; Michael J McPhaul; Zengru Wu; Amit K Ghoshal; Emma C Erlich; Kartik Mani; Gwendalyn J Randolph; John R Edwards; Philip A Mudd; Abhinav Diwan Journal: JAMA Netw Open Date: 2021-05-03
Authors: Giancarlo Pesce; Kai Triebner; Diana A van der Plaat; Dominique Courbon; Steinar Hustad; Torben Sigsgaard; Dennis Nowak; Joachim Heinrich; Josep M Anto; Sandra Dorado-Arenas; Jesús Martinez-Moratalla; Jose A Gullon-Blanco; José L Sanchez-Ramos; Chantal Raherison; Isabelle Pin; Pascal Demoly; Thorarinn Gislason; Kjell Torén; Bertil Forsberg; Eva Lindberg; Elisabeth Zemp; Rain Jogi; Nicole Probst-Hensch; Shyamali C Dharmage; Debbie Jarvis; Judith Garcia-Aymerich; Alessandro Marcon; Francisco Gómez-Real; Bénédicte Leynaert Journal: EClinicalMedicine Date: 2020-06-06